Science News

... from universities, journals, and other research organizations

How Can We Overcome The Barriers To Treating Drug-Resistant TB?

July 10, 2008 — Almost 1 in 20 cases of tuberculosis worldwide is resistant to multiple drugs (known as multidrug-resistant TB or MDR-TB) and the World Health Organization has called for a massive scale up in public health efforts to tackle these cases. Now a group of MDR-TB experts outlines its recommendations on conducting research that would help in the scale up.


Share This:

MDR-TB can be effectively treated using second-line TB drugs, though these drugs are more expensive, less potent, and less well tolerated than first-line drugs. Fewer than 2% of all patients with MDR-TB are receiving appropriate second-line treatment. The WHO has therefore called for a dramatic scale up of MDR-TB treatment as a routine component of TB control, setting a target of treating 1.6 million patients with MDR-TB by 2015. Pilot projects of MDR-TB management (known as "programmatic management of drug-resistant TB" or PMDT) in five low income settings showed treatment success rates of 59%-83%.

Frank Cobelens (KNVC Tuberculosis Foundation) and colleagues, writing on behalf of the Working Group on MDR-TB of the Stop TB Partnership, lay out their "prioritized research agenda." The agenda identifies the most important barriers to scaling up the treatment of MDR-TB and prioritizes the research questions to be addressed to overcome these barriers.

Their research priorities include:

  • new and improved tools for testing patients to see if they have drug-resistant TB
  • clinical trials of simplified and shorter second-line treatments for MDR-TB
  • new and improved strategies for diagnosis of drug-resistant TB, for helping patients complete the whole course of drug treatment, and for controlling the spread of the infection
  • understanding geographic variations in the occurrence of drug resistance
  • clinical trials to test whether giving TB drugs to people who came into contact with patients with drug-resistant TB prevents them from developing resistant TB.

With increasing recognition of drug-resistant TB worldwide, say Cobelens and colleagues, "the time has come to move PMDT in resource-limited settings beyond the limited, pilot project phase."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by Public Library of Science, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 138,600

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
Interested in ad-free access? If you'd like to read ScienceDaily without ads, let us know!
  more breaking science news

Social Networks


Follow ScienceDaily on Facebook, Twitter,
and Google:

Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

  • more science news

In Other News ...

  • more top news

Science Video News


Sick of Strep Throat

Strep throat has become harder to fight using penicillin or amoxicillin, but that's not because the Streptococci have developed a resistance to those. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: